Bantam Pharmaceutical Unveils Promising Preclinical Results for BTM-3566 at AACR Annual Meeting 2025 Bantam Pharmaceutical presents groundbreaking preclinical data for BTM-3566 at AACR 2025, showcasing solid tumor regression and FAM210B as a key biomarker.

Bantam Pharmaceutical Unveils Promising Preclinical Results for BTM-3566 at AACR Annual Meeting 2025 #United_States #Chicago #Bantam_Pharmaceutical #BTM-3566 #FAM210B